Terminated
PHASE4
INTERVENTIONAL
NCT01923480
Dosing Study of Amino Acids in Seriously Ill Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The purpose of this study is to determine the best rate of infusion of amino acids (15% CLINISOL - sulfite-free (Amino Acid) Injection) for nutrition in subjects with with stages II to IVB head and neck cancer.
Interventions
Name:
15% CLINISOL - Sulfite-free (Amino Acid) Injection
Type:
DRUG
Description:
Name:
15% CLINISOL - Sulfite-free (Amino Acid) Injection
Type:
DRUG
Description:
Name:
15% CLINISOL - Sulfite-free (Amino Acid) Injection
Type:
DRUG
Description:
Primary Outcomes
Measure:
Change in Net Protein Synthesis
TimeFrame:
One time at pre-clinisol infusion and one time at post-clinisol infusion
Description:
Trial Information
NCT ID
NCT01923480
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Baxter Healthcare Corporation
Last Updated
December 15, 2025